Roclanda receives marketing authorization in Great Britain
Click Here to Manage Email Alerts
Roclanda has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency in Great Britain, according to a press release from Aerie Pharmaceuticals.
Roclanda (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) is indicated to lower IOP in adults with primary open-angle glaucoma or ocular hypertension in whom prostaglandin or netarsudil monotherapy does not provide a sufficient decrease.
“The authorization of Roclanda in Great Britain, the only fixed-dose combination IOP-lowering therapy with a prostaglandin analogue that does not include a beta blocker, is another important regulatory milestone for Aerie on the heels of the receipt of the EC marketing authorization for Roclanda in January,” Vicente Anido Jr., PhD, chairman and CEO at Aerie, said in the release.
Roclanda received marketing authorization from the European Commission in January. It is marketed as Rocklatan in the United States and was approved by the FDA in 2019.
Read more about
Click Here to Manage Email Alerts